EuroNetHTA has released report of rapid health technology assessment for antibacterial-coated sutures for prevention of surgical site infections

18

May 2017

EuroNetHTA published rapid assessment of antibacterial-coated sutures in comparison with non-antibacterial coated sutures in relation to effectiveness and safety for the prevention of superficial and deep incisional surgical site infection in abdominal surgery in adults.

For this purpose, systematic literature review was performed with further meta-analysis. Seven randomized clinical trials (RCTs) were included into analysis of efficacy with total number of randomized patients n=3,580 patients where 52.4% of patients were treated with triclosan-coated sutures and 47.6% were non-antibacterial coated sutures. No published clinical studies on chlorhexidine-coated sutures have been identified. For safety analysis additional seven non-randomized studies were included.

A statistically significant benefit of triclosan-coated sutures in reducing the risk of total incisional surgical site infection was demonstrated in accordance to results of meta-analysis, based on moderate quality RCTs data.

The relative safety of triclosan-coated sutures could not be confirmed due to a lack of reporting of adverse effects in RCTs and non-randomized studied included into assessment.

Full report can be seen here.

Subscribe to our biweekly newsletter not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more